Do "sugar Swings" Impact the Brain Function and the Eating Behaviors of People with Type 1 Diabetes

NCT ID: NCT05487534

Last Updated: 2024-10-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-26

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In type 1 diabetes, it is common to choose the food we eat according to the blood sugar level and the insulin dose and vice versa. Beyond the nutritional aspects, the relationship to food and the resulting eating behaviors can be a source of suffering. Also, it has been reported that one out of two people over 60 years of age living with type 1 diabetes has cognitive impairment. Changes in cognitive functions can have important implications for daily well-being, diet (e.g., the ability to modulate cravings), and treatment decisions to manage diabetes.

One factor that can affect both eating behaviors and cognitive function is variation in blood glucose levels.

This research aims to better understand the impact of glycemic variability in disordered eating behaviors and cognitive impairment, and its consequences on self-management skills in people with type 1 diabetes.

The hypotheses are that i) higher glycemic variability is associated with higher disordered eating behaviors and poorer cognitive function in people with type 1 diabetes, and that differences exist between sexes, ii) higher disordered eating behaviors and poorer cognitive function are associated with lower self-management skills; and iii) cognitive impairment, interoception awareness and insulin resistance may mediate the relationship between glycemic variability and disordered eating behaviors.

This research study will contribute to highlighting the consequences of blood sugar fluctuations, "sugar swings", in daily life, in particular the way they disrupt eating behaviors and brain function. A better understanding of the mechanisms involved could eventually allow for early detection and management of these problems. Our study will also seek to understand the patients' point of view, which will allow the design of appropriate and meaningful recommendations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All assessments will be done in virtual mode through secure platforms (but also offered in person in Quebec City if needed to limit discrimination).

The study will start with an inclusion visit during which self-reported and medical data will be collected as well as some anthropometric parameters measured. Following the visit, the participant will be asked to wear a continuous glucose sensor provided by the investigator (Dexcom®) to perform a continuous glucose recording for 10 days. During this 10-day period, the participant will be required to complete:

* A food diary during 3 weekdays and 1 weekend day using the Keenoa® app.
* 3 online sessions combining questionnaires (using the Redcap platform) and computerized tests (Inquisit® platform). Each session will last approximately 45 minutes (can vary between 30 and 60 minutes).

Participants who wish to participate in the qualitative phase of this study will also be offered the opportunity to do so. Participants will be recruited consecutively until a total of 50 are reached. For this part of the study, an individual interview will be conducted by a professional specifically trained in this method of analysis. This meeting will last on average 1.5 hours, but may last up to 2.5 hours depending on the length of the discussion. There will be an audio and video recording of this meeting. The discussions will then be transcribed into text and analyzed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sugar Swing +

Patients with type 1 diabetes with a high glucose variability (i.e., a coefficient of variation \> 36% over a 10-day continuous glucose monitoring)

Observational

Intervention Type OTHER

The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.

Sugar Swing -

Patients with type 1 diabetes with low glucose variability (i.e., a coefficient of variation \< 36% over a 10-day continuous glucose monitoring)

Observational

Intervention Type OTHER

The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational

The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 1 diabetes (\> 12 months)
* Age between 18 and 65 years old
* 6.5 % \< A1C \< 9% (to avoid potential severe eating disorder)

Exclusion Criteria

* Type 2 diabetes or other form of diabetes; gastroparesis (clinical diagnosis);
* Recent (\< 6 months) major cardiovascular event (e.g. myocardial infarction, cerebrovascular accident, major revascularization)
* Recent (\< 12 weeks) severe hypoglycemia episodes (\<2.8 mmol/L or assistance from a third party)
* Recent (\< 12 weeks) changes in insulin type or delivery method
* Automated Insulin Delivery
* History of severe brain trauma, epilepsy, schizophrenia or bipolar disorders
* Inability to use a computer
* Incorrect vision or auditory problems
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CHU de Quebec-Universite Laval

OTHER

Sponsor Role collaborator

Institut de Recherches Cliniques de Montreal

OTHER

Sponsor Role collaborator

Centre d'expertise Poids, Image et Alimentation (CEPIA)

UNKNOWN

Sponsor Role collaborator

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

OTHER

Sponsor Role collaborator

Laval University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sylvain Iceta

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sylvain Iceta, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IRCM

Montreal, , Canada

Site Status RECRUITING

CHU de Québec

Québec, , Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sylvain Iceta, MD, PhD

Role: CONTACT

+1 (418) 656-8711 ext. 4565

Melissa Pelletier, M. Sc

Role: CONTACT

+1 (418) 656-8711 ext. 2136

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Maha Lebbar, MD

Role: primary

Sylvain Iceta, MD, PhD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Iceta S, Sohier L, Begin C, Brazeau AS, Rabasa-Lhoret R, Gagnon C. Impact of glycemic variability on cognitive impairment, disordered eating behaviors and self-management skills in patients with type 1 diabetes: study protocol for a cross-sectional online study, the Sugar Swing study. BMC Endocr Disord. 2022 Nov 18;22(1):283. doi: 10.1186/s12902-022-01191-4.

Reference Type DERIVED
PMID: 36401237 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MP-20-2023-6466

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.